Background. Reported data regarding chronic kidney disease (CKD) in haematopoietic stem cells transplantation (HSCT) recipients are highly discrepant. Materials and methods. We undertook a retrospective single-centre study in order to assess the rate, risk factors and outcome of HSCT-associated CKD in 123 allogeneic HSCT patients. Results. Twenty-four months after HSCT, CKD [e.g. glomerular filtration rate (GFR) estimated using the MDRD formula <60 ml/min/1.73 m 2 ] was noted in 49 patients (40%). Age ≥ 45 years, early acute kidney injury and a baseline GFR < 90 ml/min/1.73 m 2 predicted the occurrence of CKD at 24 months after HSCT. One hundred and six patients (45 with and 61 without CKD at 24 months) were followed up for more than 36 months (range 36-142). Among the 45 patients with CKD at 24 months after HSCT, CKD persisted in 30 (67%), 10 patients (22%) showed a transient improvement in GFR but retained CKD and 10 patients (22%) had a sustained improvement of GFR. Among 61 patients without CKD at 24 months after HSCT, 3 (5%) developed CKD during the follow-up. Our data indicate that HSCT-related CKD probably includes two subsets: a frequent early-onset CKD, a consequence of ARF in older patients with pre-existent renal impairment, and a rare late-onset CKD occurring more than 2 years following HSCT. Conclusions. Careful monitoring of renal function is mandatory in patients undergoing HSCT, especially old patients with pre-existent renal impairment.
Introduction
Haematopoietic stem cell transplantation (HSCT) is an established and increasingly used treatment for a wild range of haematological malignancies. Improved supportive care and transplantation procedures have translated into a dramatic improvement of overall survival of patients undergoing HSCT. However, long-term organ damage has emerged as an increasingly identified cause of morbidity and mortality in patients who have undergone HSCT [1] .
In the last decade, chronic kidney disease (CKD) arising after HSCT has been increasingly reported. However, published studies have yielded discrepant results with an incidence of HSCT-related CKD ranging from 4 to 66% of patients [2] [3] [4] [5] [6] [7] [8] [9] .
We undertook a retrospective single-centre study in order to assess the rate, risk factors and outcome of HSCTassociated CKD in long-term (>2 years) survivors of a cohort of allogeneic HSCT patients.
Patients and methods
This retrospective study was undertaken in the Departments of Nephrology and Haematology in Hôpital Necker, Paris, France. Using a computerized database, we identified all adult (>18 years) patients who had undergone an allogeneic HSCT between January 1995 and December 2005. Patients who had survived more than 2 years after HSCT were included in the study. Patient's medical records were reviewed and relevant data collected.
CKD was defined by an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m 2 noted on at least two occasions at ±3 months from the 24-month follow-up time point. GFR was estimated using the Modification of Diet in Renal Disease (MDRD) study simplified equation [10] .
Acute kidney injury (AKI) occurring within the 100 first days after HSCT was evaluated according to the RIFLE criteria [11] .
Hypertension was defined by a systolic blood pressure >140 mmHg and/or a diastolic blood pressure >90 mmHg and/or the need for antihypertensive drugs.
Results
The present study included 123 patients. The median follow-up was 64 months (range 24-159). Fourteen patients died during the study period, and 7 were lost during the follow-up.
The patient characteristics at the time of HSCT are shown in Table 1 . All patients received graft-versus-host disease (GVHD) prophylaxis with methotrexate and cyclosporine A [target therapeutic through (C0) level between 200 and 450 ng/ml for at least 9 months, then progressively decreased and stopped at 12 months in the absence of GVHD]. Forty-five patients (39%) presented an episode of AKI. No patient required renal replacement therapy.
CKD at 24 months after HSCT
CKD was noted in 49 patients (40%) 24 months after HSCT ( Table 2 ). Five patients (4%) had a severe renal impairment (eGFR <30 ml/min/1.72 m 2 ) including one patient requiring dialysis.
In univariate analysis, age ≥ 45 years, a baseline eGFR <90 ml/min/1.73 m 2 , AKI following HSCT and fludarabine use predicted the occurrence of CKD. Multiple myeloma was more frequently noted in patients with CKD compared to those without it, but difference did not reach statistical significance (20% versus 8%, P = 0.052). Gender, TBI, use of nephrotoxic drug including calcineurin inhibitors and episodes of GHVD (cutaneous or digestive) were not associated with CKD. In multivariate analysis, age ≥ 45 years, AKI and a baseline eGFR < 90 ml/min/1.73 m F/M, female/male ratio; TBI, total body irradiation; SCr, serum creatinine; GFR, glomerular filtration rate estimated using the MDRD simplified formula. CKD, chronic kidney disease; AKI, acute kidney injury.
GFR evolution during the first 24 months after HSCT
Patients with or without CKD at 24 months experienced a similar drop in GFR during the first 3 months (−28 ± 23 ml/min/1.73 m 2 versus −26 ± 22 ml/min/1.73 m 2 , respectively, P = 0.70), with a baseline GFR lower in the first group than the second (81 ± 23 ml/min/1.73 m 2 versus 98 ± 22 ml/min/1.73 m 2 , P < 0.001 (Figure 1 ). At 24 months after HSCT, eGFR had dropped by 36 ± 22 ml/min/1.73 m 2 in patients with CKD versus 17 ± 24 ml/min/1.73 m 2 in those without CKD (P < 0.001).
Long-term outcome of patients
Follow-up ≥ 3 years. One hundred and six patients, including 45 patients with and 61 patients without CKD at 24 months, were followed up for more than 36 months (range 36-142). In all, 43 patients (41%) had CKD more than 3 years after HSCT. Among 45 patients with CKD at 24 months after HSCT, 30 patients (67%) showed persistent renal impairment with a median GFR at 46.5 ml/min/1.73 m 2 at the last followup (range 24-59). Ten patients (22%) showed a slight and transient improvement in GFR but retained CKD at the last follow-up (median GFR at 57 ml/min/1.73 m 2 ). Ten patients (22%) had a sustained improvement of their renal function with a median GFR at 70.5 ml/min/1.73 m 2 at the last follow-up. Among 61 patients without CKD at 24 months after HSCT, 3 (5%) developed CKD during the follow-up (median GFR 55 ml/min/1.73 m 2 ).
Follow-up ≥ 5 years. Sixty patients had a follow-up >5 years after HSCT. At the last follow-up, 19 (31.6%) had CKD, including 16 patients who have developed CKD as early as 24 months after HSCT. Patients with CKD had a mean GFR of 49.7 ± 9 ml/min/1.73 m 2 , compared to 79.6 ± 16 ml/min/1.73 m 2 in patients without CKD.
Characteristics of patients included in the study and referred to the Nephrology Department
Twenty-three patients (18.3%) included in the present study were referred to the Nephrology Department. At the time of referral, 14 (61%) had CKD and 1 had reached endstage renal disease. Their characteristics are summarized in Table 4 .
Overall survival
Thirteen patients died mainly due to a relapse of haemopathy or HSCT-related complications (infection and chronic GVHD). The survival probability was 91% (95% CI: 84-99%) for patients without CKD at 24 months compared to 59% (95% CI: 33-99%) for patients with CKD. However, this difference did not reach statistical significance (P = 0.055).
Discussion
Data regarding the incidence of CKD in patients who had undergone HSCT are highly discrepant. This is due to the heterogeneity of included patients: the definition of CKD used, the time of CKD onset and the variable duration of follow-up. For instance, in a large study recently reported by Choi et al., the incidence of CKD, defined by a GFR < 60 ml/min/1.73 m 2 , was relatively low ∼4% at 5 years in matched sibling allogeneic and autologous HSCT and 10% in matched unrelated donor allogeneic HSCT [8] . In another study by Hingorani et al. that included a heterogeneous population of paediatric and adult patients, the incidence of CKD after HSCT was 23% [4] . In the present single-centre retrospective study, CKD was present in 40% of surviving patients at 2 years after HSCT and in 1/3 of patients with a follow-up > 5 years. In accordance with previous studies [4, 8, 9] , the rate of severe CKD (GFR <30 ml/min/1.73 m 2 ) was relatively low as only 4% of patients had CKD stage 4 and <1% of patients reached end-stage renal disease at the last follow up.
Our data indicate that renal function decline occurred mainly during the first 3 months with roughly the same loss in eGFR (∼25 ml/min/1.73 m 2 ) in patients with or without CKD. However, patients who eventually developed CKD had a lower baseline eGFR compared to patients without CKD. These data are in accordance with the finding that in multivariate analysis, age ≥ 45 years, AKI and a baseline eGFR < 90 ml/min/1.73 m 2 predicted CKD at 24 months. Older age and AKI have been previously identified as predictive factors of CKD [7] [8] [9] . Therefore, the occurrence of ARF in patients with hindered renal recovery (older age, pre-existent renal impairment) eventually leads to renal scarring and CKD. In accordance with previous reports, TBI was not associated with renal impairment at 24 months after HSCT [4, 7, 12] . This is probably due to TBI fractioning and the use of renal shield.
CKD arising > 2 years after HSCT was relatively rare in our study (3% of patients). These data are in accordance with those recently reported by Choi et al. in a recent large study [8] . Thus, HSCT-related CKD seems to include two subsets: a relatively frequent early-onset CKD (<2 years after HSCT) that arises as a consequence of AKI in a specific subtype of patients (older patients with pre-existent renal impairment) and a rare late-onset CKD (>2 years after HSCT). Among the cohort of patients included in the study, less than one-fourth of patients and less than one-third of those with CKD were referred to a nephrologist for a renal work-up. Nephropathies leading to CKD in these patients proved to be TMA, ill-defined tubulointerstitial nephropathy most probably related to drug toxicity and less frequently to membranous nephropathy. Our observations are in accordance with previous reports underlying the fact that the spectrum of chronic nephropathies extends beyond 'bone marrow transplantation (BMT) nephropathy' [13] . The latter has been individualized by Cohen et al. and defined by 'azotaemia, hypertension, and anaemia occurring 100 days or more after BMT in the absence of another nephrotoxin' [14] . Renal pathology usually discloses mesangiolysis, endothelial cells loss with accumulation of subendothelial deposits and capillary loop occlusion. These features are reminiscent not only of typical radiation nephropathy but also of TMA. In fact, the latter shares with 'HSCT-specific nephropathy' several clinical, biological as well as pathological features.
In all, careful monitoring of renal function is mandatory in patients undergoing HSCT, especially older patients with pre-existent renal impairment. A renal follow-up should be performed before HSCT and at least annually in these patients.
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